Assessing the incidence of complications and malignancies in the long-term management of benign biliary strictures with a percutaneous transhepatic drain

Munehiro Yoshitomi, MD, PhD, Ryuichi Kawahara, MD, PhD, Shinichi Taniwaki, MD, PhD, Ryuta Miodorikawa, MD, PhD, Satoki Kojima, MD, PhD, Daisuke Muroya, MD, PhD, Shoichiro Arai, MD, PhD, Takahisa Shirahama, MD, PhD, Hiroki Kanno, MD, PhD, Shogo Fukutomi, MD, PhD, Yuichi Goto, MD, PhD, Yoriko Nomura, MD, PhD, Masanori Akashi, MD, PhD, Toshihiro Sato, MD, PhD, Hisamune Sakai, MD, PhD, Toru Hisaka, MD, PhD, Yoshito Akagi, MD, PhD

Abstract

Percutaneous drainage catheters (PDCs) are required for the management of benign biliary strictures refractory to first-line endoscopic treatment. While biliary patency after PDC placement exceeds 75%, long-term catheterization is occasionally necessary. In this article, we assess the outcomes of patients at our institution who required long-term PDC placement.

A single-institution retrospective analysis was performed on patients who required a PDC for 10 years or longer for the management of a benign biliary stricture. The primary outcome was uncomplicated drain management without infection or complication. Drain replacement was performed every 4 to 12 weeks as an outpatient procedure.

Nine patients (three males and six females; age range of 48–96 years) required a long-term PDC; eight patients required the long-term PDC for an anastomotic stricture and one for iatrogenic bile duct stenosis. A long-term PDC was required for residual stenosis or patient refusal. Drain placement ranged from 157 to 408 months. In seven patients, intrahepatic stones developed, while in one patient each, intrahepatic cholangiocarcinoma or hepatocellular carcinoma occurred.

Long-term PDC has a high rate of complications; therefore, to avoid the need for using long-term placement, careful observation or early surgical interventions are required.

Abbreviations: CT = computed tomography, PDCs = percutaneous drainage catheters, PTCSL = percutaneous transhepatic cholangioscopic lithotripsy.
Keywords: benign biliary strictures, long-term management, percutaneous transhepatic drain

1. Introduction

Percutaneous drainage catheter (PDC) placement for 6 to 12 months is an effective strategy for achieving permanent patency in the treatment of a benign biliary stricture in patients who are not surgical candidates or have failed endoscopic management.[1] Twenty months after catheter removal, primary patency was reported in 81.25% of liver transplant recipients and 89.5% of all other patients.[2] While all-comers statistics are encouraging,[3] Weber et al.[4] in their management of 44 patients with benign anastomotic strictures after bilioenterostomy, who were therefore not endoscopy candidates, reported a success rate of PDC of 61.4% at a mean of 53.7 months of follow-up.

Long-term PDC may be the only option for patients who refuse surgical management or whose pathology or host characteristics make them poor surgical candidates. It is fraught with potential complications, including skin changes at the insertion site, poor quality of life, long-term radiation exposure during catheter exchanges,[5] and chronic inflammatory changes in the biliary duct that may predispose to malignancy.[6] Understanding long-term PDC risks is critical for assisting patients with informed decision-making and anticipating complications. However, few reported studies have evaluated these patients as a cohort. Thus, we aimed to evaluate our institutional experience with long-term PDC management of benign biliary stricture.
2. Methods

This is an institutional review board-approved retrospective analysis of patients who underwent PDC with chronic drain placement of ≥10 years at a single large academic medical center from April 1973 to March 2019.

The primary outcome was successful drain maintenance, which is defined as PDC without significant complication requiring an unplanned procedure against biliary tree malignancy development. Additional factors of interest included patient age and sex, PDC replacement interval, tube size, and length of drain placement.

This study was approved by the Institutional review board, Kurume University Hospital (approval no. 2021-012) and performed in accordance with the Declaration of Helsinki. The written informed consent requirement was waived off because of the retrospective design.

The descriptive statistics were calculated. All values were presented as mean ± standard deviation or ratio (percentage), unless otherwise stated. No comparative statistical analysis was performed.

3. Results

During the study period, a total of 2407 PDCs were placed. Of these, 34 were for a postoperative benign biliary stricture, 19 required a PDC for ≥1, and 9 had a drain for ≥10 years.

Subjects’ included three males and six females (age range: 48–96 years) with the following comorbidities: dementia (1); liver disease (severe: 1 and mild: 1); uncomplicated diabetes mellitus (2); Charlson’s risk index (high: 1 and medium: 3).

The indication for PDC placement was an anastomotic stricture following cholangiojejunostomy in eight cases and iatrogenic bile duct stenosis in one case (Table 1). The reasons for the inability of drain removal included residual stenosis (8 patients) and patient refusal (1 patient).

Drain replacement was performed at a 4- to 12-week interval as an outpatient procedure (mean interval between exchanges: 5.8 ± 0.72 weeks). However, the other ten patients required a PDC for ≥1 and <10 years (mean interval between exchanges: 10.1 ± 2.31 weeks). Seven patients developed symptomatic intrahepatic stones for which percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) was required once every 6 to 12 weeks; however, currently, her drain clogs due to the biliary sludge more frequently and replacements are required every 6 to 8 weeks. Although surgery was considered, the patient refused the operative management and wished to continue with regular drain replacements. This continues at the age of 50, 31 years after her initial PDC placement.

### Table 1

| Age  | Condition                      | Surgery                        | Placement period (mo) | Replacement interval (wk) | Tube      | Charlson risk index |
|------|--------------------------------|--------------------------------|-----------------------|--------------------------|-----------|---------------------|
| 48   | Congenital biliary dilatation  | Cholangiojejunostomy           | 408                   | 6                        | 18F internal fistula |                     |
| 50   | Congenital biliary dilatation  | Cholangiojejunostomy           | 224                   | 8                        | 10F internal fistula | Diabetes mellitus uncomplicated: 1 |
| 63   | Congenital biliary dilatation  | Cholangiojejunostomy           | 351                   | 3                        | 16F internal fistula | Liver disease severe: 3 |
| 71   | Congenital biliary dilatation  | Cholangiojejunostomy           | 182                   | 4                        | 10F internal fistula |                      |
| 71   | Congenital biliary dilatation  | Cholangiojejunostomy           | 227                   | 4                        | 12F internal fistula |                      |
| 96   | Cholelithiasis, bile duct injuries | Cholangiojejunostomy        | 178                   | 8                        | 16F internal fistula | Dementia: 1 diabetes mellitus uncomplicated: 1 |
| 67   | Bile duct duodenal fistula     | Cholangiojejunostomy, hepatotomy | 157                   | 8                        | 14F internal fistula | Liver disease mild: 1 |
| 87   | Cholelithiasis, bile duct injuries | Cholangiojejunostomy         | 275                   | 2                        | 18F internal fistula |                     |
| 84   | Neurilemoma                    | Cholangiojejunostomy           | 192                   | 9                        | 14F internal fistula |                     |

(High: 1/medium: 3)
of 67, the patient had repetitive episodes of refractory cholangitis (Fig. 2). Since distinguishing the cholangitis from an abscess was difficult, a contrast-enhanced computed tomography (CT) scan and liver biopsy were performed, and intrahepatic cholangiocarcinoma was diagnosed. Unfortunately, her disease was unresectable. After 3 months of attempted multidisciplinary treatment with chemotherapy without improvement, the patient transitioned to palliative care and died. In this particular case, bile cytodiagnosis came back negative. This occurred despite the close observation for 10 years due to concern for cancer.

3.4. Case 4

A 43-year-old female underwent extrahepatic bile duct resection and cholangiojejunostomy for congenital biliary dilatation at another hospital. At the age of 50, she developed an anastomotic stricture and intrahepatic stones, requiring PDC and PTCSL. At that point, no causal viral infection or liver cirrhosis was evident and there was a secondary biliary cirrhosis accompanied by cholestasis, making surgical treatment difficult. Her stenosis did not improve, requiring chronic PDC management. At the age of 71, she developed hepatocellular carcinoma (Fig. 3), but cancer treatment was unable to be performed because of her poor hepatic functional reserve. The patient transitioned to palliative care and passed away shortly after that.

4. Discussion

Although PDC placement is largely effective for a period of 6 to 12 months, selected patients may require long-term or indefinite therapy due to surgical contraindication, distorted anatomy, or their own preference. In a retrospective analysis of our experience
with nine patients who required PDC for >10 years, we observed a high rate of intrahepatic stone formation (77.8%) and malignancy (22.2%).

Over the course of patient therapy, more frequent PDC exchanges (exchange frequency: 5.8 weeks) were required, which was significantly shorter than the 12 ± 4.5-week interval previously reported by Weber et al. More frequent PDC changes appeared to be related to an increased biliary sludge volume noted on the PDC tube during exchanges. The increased sludge formation is a sequela of secondary sclerosing cholangitis, which is commonly reported in long-term biliary obstructions. Damage to the biliary tree from a prior surgery or the benign biliary stricture itself could compromise the biliary tree’s natural defenses against potentially toxic bile salts. The resulting increase in inflammatory cytokines released from damaged endothelium can lead to further progressive tissue damage and hepatic injury. As per the results of the previous studies, the mean follow-up period was 4 to 5 years without these sequelae; therefore, it appears that a significant duration of chronic biliary tree inflammation is required before the onset of this condition. However, the sequelae of secondary sclerosing cholangitis include hepatic damage and an increased risk of malignancy.

As many of the patients in our series had no other viable option in the management of their benign biliary stricture other than PDC, we hypothesize that reducing the degree of bile acid buildup may result in improved long-term outcomes or at least delay the progression of chronic inflammatory changes.

While the surgical management of benign biliary strictures has improved, perioperative and late complication rates of up to 25% have been reported. These rates discouraged us from performing surgery in one patient in whom an external fistula used at a late stage resulted in a significant decrease in her quality of life. Furthermore, endoscopic management of benign biliary strictures is recommended whenever possible while most of our patients were not surgical candidates because of anatomical reasons, the outcomes of this work reveal that chronic PDC should be avoided wherever possible. The risks of surgery versus the risks of chronic PDC should be discussed with patients. Furthermore, it should be emphasized that long-term damage related to chronic PDC and secondary sclerosing cholangitis may not permit surgery in the future.

Carcinogenesis was observed in two cases (22.22%) in our series. In addition to hepatolithiasis, chronic bile duct damage/inflammation, and cholangiojejunostomy are known risk factors for intrahepatic cholangiocarcinoma. The possibility that PDCs themselves also contributed to this proinflammatory milieu cannot be discounted. However, it is likely that any impact of the PDC minimally affected the vicious cycles of inflammation that existed before and during PDC therapy. In our patient group, more vigilant surveillance could have enabled earlier cancer detection; however, surveillance alone cannot prevent cancer, and no preventative options were available. We hypothesize that the key to managing the oncologic risks of patients with long-term PDCs is controlling the cholestasis and secondary sclerosing cholangitis resulting from significant biliary sludge buildup. While definitive management with hepatectomy and biliary tract reconstruction was not viable for patients in our series, we believe that pilot studies involving medical therapies, such as those for biliary dyspepsia, may be important in improving the longevity and quality of life of patients who require long-term care with PDC.

In addition to its nature as a retrospective study, this study has several notable limitations. It includes a small sample size to evaluate a rather rare clinical indication. Therefore, the patients in this cohort poorly represent the entire population of patients who require long-term PDC. Furthermore, the treatment period of these patients spanned decades, during which multiple advances have occurred in minimally invasive endoscopy for benign biliary strictures. Finally, without a treatment group, we have only historical comparisons to evaluate our complication and malignancy rates. While a prospective trial is unlikely, given the rarity of the modern indications for chronic PDC, a multicenter retrospective analysis with demographic and pathology-matched controls would significantly improve the interpretability and reliability of our findings.

In conclusion, we report a high rate of complications and malignancy in the chronic management of benign biliary sclerosis with PDC. Therefore, alternative management should be considered whenever possible. Future assessment of potential ways to improve the longevity and quality of life of patients who can only be managed with PDC is required.

Acknowledgments
The authors thank Crimson Interactive Pvt. Ltd (Ulatus)—www.ulatus.jp for their assistance in manuscript translation and editing. The authors would like to thank all the doctors who specialize in PTBD at Kurume University School of Medicine.

Author contributions
Acquisition of data: Shinichi Taniwaki, Ryuta Midorikawa, Satoki Kojima, Daisuke Muroya, Shoichiro Arai, Takahisa Shirahama.
All authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Analysis and interpretation of data: Hiroki Kanno, Shogo Fukutomii, Yuichi Goto, Yoriko Nomura, Masanori Akashi, Toshihiro Sato, Hisamune Sakai.
Critical revision: Ryuichi Kawahara, Toru Hisaka, Yoshito Akagi.
Drafting the manuscript: Munehiro Yoshitomi.
Study conception and design: Munehiro Yoshitomi, Ryuichi Kawahara, Toru Hisaka, Yoshito Akagi.
Conceptualization: Munehiro Yoshitomi, Ryuichi Kawahara, Toru Hisaka, Yoshito Akagi.
Data curation: Shinichi Taniwaki, Ryuta Midorikawa, Satoki Kojima, Daisuke Muroya, Shoichiro Arai, Takahisa Shirahama.
Formal analysis: Hiroki Kanno, Shogo Fukutomii, Yuichi Goto, Yoriko Nomura, Masanori Akashi, Toshihiro Sato, Hisamune Sakai.
Investigation: Hiroki Kanno, Shogo Fukutomii, Yuichi Goto, Yoriko Nomura, Masanori Akashi, Toshihiro Sato, Hisamune Sakai.
Writing – original draft: Munehiro Yoshitomi.
Writing – review & editing: Ryuichi Kawahara, Toru Hisaka, Yoshito Akagi.
References

[1] Keane MG, Devlin J, Harrison P, Masadeh M, Arain MA, Joshi D. Diagnosis and management of benign biliary strictures post liver transplantation in adults. Transplant Rev (Orlando) 2021;35:100593.

[2] Kapoor BS, Mauri G, Lorenz JM. Management of biliary strictures: state-of-the-art review. Radiology 2018;289:590–603.

[3] Glas L, Courbière M, Ficarelli S, Milot L, Mennesson N, Pilleul F. Long-term outcome of percutaneous transhepatic therapy for benign biliary-enteric anastomotic strictures. J Vasc Interv Radiol 2008;19:1336–43.

[4] Weber A, Rosca B, Neu B, et al. Long-term follow-up of percutaneous transhepatic biliary drainage (PTBD) in patients with benign biliary-enteric anastomosis stricture. Endoscopy 2009;41:323–8.

[5] Schmitz D, Vogl T, Nour-Eldin NA, et al. Patient radiation dose in percutaneous biliary interventions: recommendations for DRLs on the basis of a multicentre study. Eur Radiol 2019;29:3390–400.

[6] Fidelman N. Benign biliary strictures: diagnostic evaluation and approaches to percutaneous treatment. Tech Vasc Interv Radiol 2015;18:210–7.

[7] Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 2009;6:287–95.

[8] Martins P, Verdelho Machado M. Secondary sclerosing cholangitis in critically ill patients: an underdiagnosed entity. GE Port J Gastroenterol 2020;27:103–14.

[9] Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005;100:1330–3.

[10] Tocchi A, Costa G, Lepre L, Liotta G, Mazzoni G, Sita A. The long-term outcome of hepaticojejunostomy in the treatment of benign bile duct strictures. Ann Surg 1996;224:162–7.

[11] Tocchi A, Mazzoni G, Liotta G, Lepre L, Cassini D, Miccini M. Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients. Ann Surg 2001;234:210–4.

[12] Ohira S, Sasaki M, Harada K, et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-α and stromal-derived factor-1 released in stroma. Am J Pathol 2006;168:1153–68.

[13] Kadaba RS, Bowers KA, Khorsandi S, et al. Complications of biliary-enteric anastomoses. Ann R Coll Surg Engl 2017;99:210–5.

[14] Strong RW. Late bile duct cancer complicating biliary-enteric anastomosis for benign disease. Am J Surg 1999;177:472–4.